The Latest Breaking News from Abbott

Diversified healthcare company Abbott (ABT) has demonstrated significant innovations across its segments, and given its dominant market position, the company’s prospects look bright. The stock could be a solid choice as it is well-positioned to survive short-term market fluctuations. Let’s discuss this in detail….

Medical device company Abbott Laboratories (ABT) reported impressive first-quarter results and affirmed its strong performance guidance for fiscal 2022. Furthermore, the company is well-positioned to benefit from its diversified business. However, amid the heightened market volatility, the stock is trading 25.5% below its 52-week high. So, the current dip in…

Problems for Abbott Laboratories' (NYSE: ABT) Sturgis plant in Michigan for baby formula powder refuse to subside. The FDA was recently notified of another infant's death who was given formula made at Abbott's Sturgis facility.

Shortage of formula has created more headaches for Biden administration

U.S. Food and Drug Administration officials are investigating the death of another infant who was given formula made by Abbott Laboratories.

The medical device maker will keep its headquarters in the northern suburbs but says a downtown location works for employees who want to avoid a long commute.

Production halt at Abbott Laboratories in Michigan will probably extend shortages for ‘a few weeks’

It is unclear when the facility will restart production

Less than two weeks after restarting formula production at its Michigan facility, Abbott has again had to halt manufacturing there amid flooding.

Abbott's Sturgis, Mich., plant was open for less than two weeks before it had to close again after flooding from severe weather. The company said it hopes to resume production in a few weeks.

Barely two weeks after production restarted at a Michigan plant that supplies baby formula, flooding in the area has shut down the work as supply continues to dry up nationwide.